US9444503 — Active signal processing personal health signal receivers
Method of Use · Assigned to Proteus Digital Health Inc · Expires 2027-11-19 · 2y remaining
What this patent protects
This patent protects a receiver that can accurately decode low-level signals from an in vivo transmitter inside the body, even with significant noise.
USPTO Abstract
The invention provides a receiver associated with a body, e.g., located inside or within close proximity to a body, configured to receive and decode a signal from an in vivo transmitter which located inside the body. Signal receivers of the invention provide for accurate signal decoding of a low-level signal, even in the presence of significant noise, using a small-scale chip, e.g., where the chip consumes very low power. Also provided are systems that include the receivers, as well as methods of using the same.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2169 |
— | Abilify |
U-2169 |
— | Abilify |
U-2169 |
— | Abilify |
U-2169 |
— | Abilify |
U-2169 |
— | Abilify |
U-2169 |
— | Abilify |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.